GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
M

Medrx Co 4586.T · JPY

Health Care · Tokyo Stock Exchange · 🇯🇵 Japan

Compare

38

0.00%

Close of 9 Nov 2026, in JPY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in JPY, from our data supplier.

FY2025

Revenue

¥128.1m

FY2016FY2025

Net income

−¥937.4m

FY2016FY2025

Free cash flow

−¥970.9m

FY2016FY2025

Shareholders' equity

¥2.05bn

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue¥128.1m¥257.9m¥29.5m¥59.5m¥8.3m¥115.1m¥169.9m¥8.4m¥198.2m¥22.3m
Gross profit¥113.0m¥219.2m−¥18.4m¥10.4m−¥54.2m¥55.3m¥124.4m−¥34.0m¥132.0m−¥42.8m
Research and development¥838.8m¥809.8m¥694.1m¥877.7m¥737.1m¥914.7m¥1.47bn¥943.6m¥832.0m¥1.02bn
Operating income−¥942.0m−¥800.5m−¥933.6m−¥1.11bn−¥1.06bn−¥1.13bn−¥1.63bn−¥1.27bn−¥1.02bn−¥1.34bn
Net income−¥937.4m−¥806.8m−¥932.9m−¥1.11bn−¥1.06bn−¥1.11bn−¥1.62bn−¥1.27bn−¥884.4m−¥1.26bn
Diluted earnings per share-14.52-16.99-24.32-39.37-44.74-60.98-125.39-124.14-101.09-147.87

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assets¥2.16bn¥2.27bn¥2.05bn¥1.40bn¥2.11bn¥2.30bn¥2.05bn¥2.31bn¥2.13bn¥3.08bn
Cash and short-term investments¥1.75bn¥1.98bn¥1.72bn¥994.0m¥1.70bn¥1.81bn¥1.41bn¥1.80bn¥1.74bn¥2.64bn
Total liabilities¥108.5m¥107.0m¥127.5m¥185.6m¥153.1m¥149.9m¥126.8m¥180.9m¥99.1m¥572.6m
Debt—————¥50.0m———¥394.9m
Shareholders' equity¥2.05bn¥2.17bn¥1.92bn¥1.21bn¥1.96bn¥2.15bn¥1.92bn¥2.13bn¥2.03bn¥2.51bn
Shares outstanding65m47m38m28m24m18m13m10m9m9m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations−¥888.1m−¥803.0m−¥913.0m−¥1.07bn−¥923.7m−¥985.4m−¥1.55bn−¥1.26bn−¥854.3m−¥1.22bn
Capital spending−¥82.8m−¥265,000−¥759,000−¥2.0m−¥2.5m−¥39.4m−¥252.6m−¥42.5m−¥50.5m−¥6.9m
Free cash flow−¥970.9m−¥803.3m−¥913.8m−¥1.08bn−¥926.2m−¥1.02bn−¥1.80bn−¥1.30bn−¥904.8m−¥1.22bn

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Revenue¥6.0m¥5.7m¥9.3m¥100.0m¥16.6m¥2.2m¥2.7m¥23.7m
Gross profit¥234,000¥3.9m¥7.1m¥98.5m¥15.0m−¥7.6m−¥6.7m¥16.5m
Operating income−¥297.9m−¥246.2m−¥199.7m−¥133.0m−¥190.3m−¥419.0m−¥413.4m−¥244.0m
Net income−¥312.7m−¥238.4m−¥167.9m−¥139.8m−¥200.4m−¥429.1m−¥486.6m−¥259.2m
Diluted earnings per share-5.25-4.00-2.60-2.17-3.10-6.65-10.24-5.46
Total assets¥1.74bn¥2.00bn¥2.16bn¥2.21bn¥1.93bn¥1.83bn¥2.27bn¥2.71bn
Cash and short-term investments¥1.14bn¥1.46bn¥1.75bn¥1.75bn¥1.67bn¥1.55bn¥1.98bn¥2.33bn
Shareholders' equity¥1.59bn¥1.83bn¥2.05bn¥2.15bn¥1.87bn¥1.73bn¥2.17bn¥2.62bn

Financial ratios

Data as of 13 Oct 2026

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2013FY2012
Gross margin88.2%85.0%-62.4%17.6%-649.7%48.1%—————
Operating margin-735.5%-307.5%-3161.0%-1851.2%-12709.3%-982.2%—————
Net margin-731.8%-312.8%-3158.7%-1868.0%-12692.6%-968.5%—————
Return on equity-45.7%-37.2%-48.5%-91.6%-54.2%-51.9%—————
Return on assets-43.4%-35.5%-45.5%-79.5%-50.3%-48.5%—————
Free cash flow yield-21.9%-29.7%-41.7%-66.6%-68.2%-90.8%—————
Revenue growth-50.3%773.3%-50.3%612.4%-92.7%-32.2%—————
Earnings growth16.2%-13.5%-16.0%4.8%-4.9%-31.0%—————
Current ratio23.62x19.73x17.85x6.87x13.95x15.38x—————
Debt to equity———0.00x0.00x0.02x0.00x0.00x0.00x——
Equity ratio95.0%95.3%93.7%86.7%92.7%93.5%—————
Interest coverage———-584.76x-720.45x-3080.16x-331.36x——-77.35x-129.03x
R&D as a share of sales654.9%314.0%2350.2%1475.7%8827.9%794.8%—————
Buybacks as a share of market value-35.9%-23.8%-35.9%-19.1%-29.6%-41.8%—————

Growth per year

Compound annual rate

3 years5 years10 years
Revenue29.1%2.2%13.0%
Operating income-5.3%-3.6%-0.6%
Net income-5.5%-3.4%0.7%

Average margins

Over each period

1 year3 years5 years10 years
Gross margin86.1%68.3%54.4%43.9%
Operating margin-451.4%-796.5%-998.4%-1182.5%
Net margin-451.8%-797.5%-996.3%-1146.8%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings-7.4-4.8-6.2-2.4-2.9-3.5-2.4-4.5-11.8-3.2
Price to sales54.415.1196.245.1363.133.523.1—52.5181.8

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.